Findings

What do systematic reviews say?

2,087 questions · 2,360 findings · 390 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 224 · 9.5%GRADE not reported 603 · 25.6%Very low 555 · 23.5%Low 548 · 23.2%Moderate 312 · 13.2%High 118 · 5%

Family‐centred care vs control

Family health‐enhancing lifestyle or behavioural outcomes Timing: the longest time point available for each study Direction of effect: higher beneficial · Indigenous children aged < 5 years

1 finding from 1 review

Family‐centred interventions for Indigenous early childhood well‐being by primary healthcare services 2022 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 1969 participants
Very low

Family‐centred care vs control

Psychological health of parent/carer Timing: the longest time point available for each study Direction of effect: higher beneficial · Indigenous children aged < 5 years

1 finding from 1 review

Family‐centred interventions for Indigenous early childhood well‐being by primary healthcare services 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 975 participants
Very low

Family‐centred care vs control

Harms · Indigenous children aged < 5 years

1 finding from 1 review

Family‐centred interventions for Indigenous early childhood well‐being by primary healthcare services 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Grip strength ‐ Vitamin D · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Effect on breast cancer‐specific quality of life (BCS‐QoL) · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 147 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Health‐related quality of life (HRQoL) · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 208 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Safety of systemic therapies for the treatment of AIMSS · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1250 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in pain from baseline to end of intervention · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1099 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in stiffness from baseline to end of intervention · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 295 participants
Very low

Intervention not reported

Cognitive function using validated neuropsychological tests · patients with a primary brain tumour, within two weeks of surgical intervention

1 finding from 1 review

Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 53 participants
Very low

Hydrocortisone vs placebo

Severity of PTSD symptoms · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propranolol vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

Severity of PTSD symptoms ‐ Clinician‐rated · adults (aged 18 and older) exposed to a traumatic event

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Gabapentin vs placebo

Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

PTSD rate at 3 months · adults (aged 18 and older) exposed to a traumatic event

It is very uncertain whether gabapentin changes PTSD rate at 3 months compared with placebo (very low certainty).

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.8 [0.18, 3.59]
1 study · 26 participants
Very low

Gabapentin vs placebo

Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

PTSD rate at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found